Research ExplorerPublicationsImpact of IL28B genotype on the early and sustained virologi...

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C

Standard

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. / Stättermayer, Albert Friedrich; Stauber, Rudolf; Hofer, Harald; Rutter, Karoline; Beinhardt, Sandra; Scherzer, Thomas Matthias; Zinober, Kerstin; Datz, Christian; Maieron, Andreas; Dulic-Lakovic, Emina; Kessler, Harald H; Steindl-Munda, Petra; Strasser, Michael; Krall, Christoph; Ferenci, Peter.

In: CLIN GASTROENTEROL H, Vol. 9, No. 4, 01.04.2011, p. 344-350.e2.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stättermayer, AF, Stauber, R, Hofer, H, Rutter, K, Beinhardt, S, Scherzer, TM, Zinober, K, Datz, C, Maieron, A, Dulic-Lakovic, E, Kessler, HH, Steindl-Munda, P, Strasser, M, Krall, C & Ferenci, P 2011, 'Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C', CLIN GASTROENTEROL H, vol. 9, no. 4, pp. 344-350.e2. https://doi.org/10.1016/j.cgh.2010.07.019

APA

Stättermayer, A. F., Stauber, R., Hofer, H., Rutter, K., Beinhardt, S., Scherzer, T. M., Zinober, K., Datz, C., Maieron, A., Dulic-Lakovic, E., Kessler, H. H., Steindl-Munda, P., Strasser, M., Krall, C., & Ferenci, P. (2011). Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. CLIN GASTROENTEROL H, 9(4), 344-350.e2. https://doi.org/10.1016/j.cgh.2010.07.019

Vancouver

Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. CLIN GASTROENTEROL H. 2011 Apr 1;9(4):344-350.e2. https://doi.org/10.1016/j.cgh.2010.07.019

Bibtex

@article{38cff94e81e547319e7c562817ccd4d2,
title = "Impact of IL28B genotype on the early and sustained virologic response in treatment-na{\"i}ve patients with chronic hepatitis C",
abstract = "BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in the gene that encodes interleukin (IL)-28B predict response of patients with chronic hepatitis C to antiviral therapy. We investigated the roles of polymorphisms rs12979860 and rs8099917 on the early virologic response of treatment-na{\"i}ve patients.METHODS: SNPs were identified by real-time polymerase chain reaction analysis of samples from 682 patients (genotype [GT]1=372, GT2/3=208, GT4=102) who were treated with 180 μg pegylated interferon-α2a and 400 or 800 mg (GT2/3, depending on the protocol) or 1000-1200 mg (GT1/4) ribavirin/day. The duration of treatment was 24 (GT2/3) or 24-72 weeks (GT1/4).RESULTS: Patients with C/C also had higher rates of rapid virologic response (RVR) (GT1, 38.3% vs 11.6%; GT4, 76.5% vs 23.5%; both P<.001) and sustained virologic responses (SVRs) (GT1, 79.1% vs 43.2%; GT4, 85.3% vs 44.1%; both P<.001). In patients with GT2/3, the RVR was more frequent in carriers of C/C (75.3% vs 52.6%, P<.01), but SVR rates were similar between those with C/C and T (80.5% vs 74.4%, P=.31). Results for rs8099917 were comparable. The positive predictive value of rs12979860 C/C for SVR was higher than that of rs8099917 T/T (80.5% vs 71.6%). Overall, RVR was the best predictor of SVR. In patients who did not have GT1, IL28B polymorphisms did not affect the SVR if RVR data were included in the multivariate analysis.CONCLUSIONS: An early virologic response to pegylated interferon and ribavirin is more likely among carriers of rs12979860 C/C and rs8099917 T/T, which might underlie their high rates of SVR. Determination of the IL28B genotype and whether patients have an RVR might be used in future studies of patients with hepatitis C virus genotype 1 or 4.",
keywords = "Adult, Antiviral Agents, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Interleukins, Male, Middle Aged, Polyethylene Glycols, Polymorphism, Single Nucleotide, Recombinant Proteins, Ribavirin, Treatment Outcome, Viral Load",
author = "St{\"a}ttermayer, {Albert Friedrich} and Rudolf Stauber and Harald Hofer and Karoline Rutter and Sandra Beinhardt and Scherzer, {Thomas Matthias} and Kerstin Zinober and Christian Datz and Andreas Maieron and Emina Dulic-Lakovic and Kessler, {Harald H} and Petra Steindl-Munda and Michael Strasser and Christoph Krall and Peter Ferenci",
note = "Copyright {\textcopyright} 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2011",
month = apr,
day = "1",
doi = "10.1016/j.cgh.2010.07.019",
language = "English",
volume = "9",
pages = "344--350.e2",
journal = "CLIN GASTROENTEROL H",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C

AU - Stättermayer, Albert Friedrich

AU - Stauber, Rudolf

AU - Hofer, Harald

AU - Rutter, Karoline

AU - Beinhardt, Sandra

AU - Scherzer, Thomas Matthias

AU - Zinober, Kerstin

AU - Datz, Christian

AU - Maieron, Andreas

AU - Dulic-Lakovic, Emina

AU - Kessler, Harald H

AU - Steindl-Munda, Petra

AU - Strasser, Michael

AU - Krall, Christoph

AU - Ferenci, Peter

N1 - Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in the gene that encodes interleukin (IL)-28B predict response of patients with chronic hepatitis C to antiviral therapy. We investigated the roles of polymorphisms rs12979860 and rs8099917 on the early virologic response of treatment-naïve patients.METHODS: SNPs were identified by real-time polymerase chain reaction analysis of samples from 682 patients (genotype [GT]1=372, GT2/3=208, GT4=102) who were treated with 180 μg pegylated interferon-α2a and 400 or 800 mg (GT2/3, depending on the protocol) or 1000-1200 mg (GT1/4) ribavirin/day. The duration of treatment was 24 (GT2/3) or 24-72 weeks (GT1/4).RESULTS: Patients with C/C also had higher rates of rapid virologic response (RVR) (GT1, 38.3% vs 11.6%; GT4, 76.5% vs 23.5%; both P<.001) and sustained virologic responses (SVRs) (GT1, 79.1% vs 43.2%; GT4, 85.3% vs 44.1%; both P<.001). In patients with GT2/3, the RVR was more frequent in carriers of C/C (75.3% vs 52.6%, P<.01), but SVR rates were similar between those with C/C and T (80.5% vs 74.4%, P=.31). Results for rs8099917 were comparable. The positive predictive value of rs12979860 C/C for SVR was higher than that of rs8099917 T/T (80.5% vs 71.6%). Overall, RVR was the best predictor of SVR. In patients who did not have GT1, IL28B polymorphisms did not affect the SVR if RVR data were included in the multivariate analysis.CONCLUSIONS: An early virologic response to pegylated interferon and ribavirin is more likely among carriers of rs12979860 C/C and rs8099917 T/T, which might underlie their high rates of SVR. Determination of the IL28B genotype and whether patients have an RVR might be used in future studies of patients with hepatitis C virus genotype 1 or 4.

AB - BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in the gene that encodes interleukin (IL)-28B predict response of patients with chronic hepatitis C to antiviral therapy. We investigated the roles of polymorphisms rs12979860 and rs8099917 on the early virologic response of treatment-naïve patients.METHODS: SNPs were identified by real-time polymerase chain reaction analysis of samples from 682 patients (genotype [GT]1=372, GT2/3=208, GT4=102) who were treated with 180 μg pegylated interferon-α2a and 400 or 800 mg (GT2/3, depending on the protocol) or 1000-1200 mg (GT1/4) ribavirin/day. The duration of treatment was 24 (GT2/3) or 24-72 weeks (GT1/4).RESULTS: Patients with C/C also had higher rates of rapid virologic response (RVR) (GT1, 38.3% vs 11.6%; GT4, 76.5% vs 23.5%; both P<.001) and sustained virologic responses (SVRs) (GT1, 79.1% vs 43.2%; GT4, 85.3% vs 44.1%; both P<.001). In patients with GT2/3, the RVR was more frequent in carriers of C/C (75.3% vs 52.6%, P<.01), but SVR rates were similar between those with C/C and T (80.5% vs 74.4%, P=.31). Results for rs8099917 were comparable. The positive predictive value of rs12979860 C/C for SVR was higher than that of rs8099917 T/T (80.5% vs 71.6%). Overall, RVR was the best predictor of SVR. In patients who did not have GT1, IL28B polymorphisms did not affect the SVR if RVR data were included in the multivariate analysis.CONCLUSIONS: An early virologic response to pegylated interferon and ribavirin is more likely among carriers of rs12979860 C/C and rs8099917 T/T, which might underlie their high rates of SVR. Determination of the IL28B genotype and whether patients have an RVR might be used in future studies of patients with hepatitis C virus genotype 1 or 4.

KW - Adult

KW - Antiviral Agents

KW - Female

KW - Genotype

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Interleukins

KW - Male

KW - Middle Aged

KW - Polyethylene Glycols

KW - Polymorphism, Single Nucleotide

KW - Recombinant Proteins

KW - Ribavirin

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1016/j.cgh.2010.07.019

DO - 10.1016/j.cgh.2010.07.019

M3 - SCORING: Journal article

C2 - 20728570

VL - 9

SP - 344-350.e2

JO - CLIN GASTROENTEROL H

JF - CLIN GASTROENTEROL H

SN - 1542-3565

IS - 4

ER -